Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults. It primarily affects the elderly and occurs twice as often in males than in females. 1 The disease is influenced by complex heterogeneous genetic and microenvironmental factors that can result in different clinical courses. 2, 3 The pathogenesis of CLL varies depending on molecular heterogeneity background, mutational load and specific genomic aberrations. 4, 5 Genome-wide association studies identified many susceptibility loci involved in B-cell biology and CLL development. [6] [7] [8] One study revealed that the telomere/telomerase system may be impaired in the early stages of CLL. 9 Also, several studies focused on the potential prognostic significance of telomere length and human telomerase reverse transcriptase (hTERT) activity in CLL.
Human telomerase activity is regulated by expression of the telomerase reverse transcriptase (TERT) gene that encodes the catalytic subunit of telomerase. 14 The TERT gene is located on chromosome 5p15.33 and consists of 16 exons and 15 introns spanning over 40 kb, and is essential for maintenance of telomere length by protecting chromosome ends. It has been documented that single-nucleotide polymorphisms (SNPs) within the TERT gene may affect the length of telomeres and telomerase activity, thus contributing to CLL disease susceptibility. 7, 8, [15] [16] [17] Main processes such as transcription, alternative mRNA splicing, phosphorylation and many other changes, including mutations and gene variants of TERT, have been shown to play pivotal roles in the regulation of telomerase activity and cancer risk. 18, 19 Alternative splicing of hTERT mRNA is considered to be one of the most precise regulators of telomerase activity in human cells. Induction of an hTERT splicing variant was associated with increased expression of the apoptotic endonuclease EndoG, a splicing regulator. It was demonstrated that EndoG (an apoptotic endonuclease capable of destroying both DNA and RNA) induced alternative splicing of the telomerase catalytic subunit hTERT and inhibited telomerase activity in normal human CD4 + T lymphocytes. 20, 21 The promoter region and sequences upstream interact with both positive and negative regulators of the TERT gene through many transcriptional binding sites. 22, 23 It has been demonstrated that TERT promoter activity depends on variable numbers of tandem repeats (VNTRs), such as MNS16A, which constitutes a binding site for a transcription factor GATA binding protein 1 (GATA-1). 24 Research on the functional significance of this genetic polymorphism showed that shorter MNS16A is related to higher TERT promoter activity. 24, 25 This functional polymorphism may play an important role in human longevity, disease progression and response to therapy of patients with non-Hodgkin's B-cell lymphomas and the development of other cancers. [26] [27] [28] [29] Mechanisms underlying telomere maintenance and telomerase reactivation in leukemogenesis are currently being investigated. Increasing data on the CLL genetic background and landscape, including the role of many gene variants in disease initiation and progression in the context of telomere length, may be crucial for understanding CLL pathogenesis. 30, 31 This prompted us to investigate the role of MNS16A VNTR and selected SNPs located within the TERT gene in relation to telomere length and stage of disease in non-treated patients with CLL. TERT SNPs were chosen using the SNP Function Prediction tool of the National Institute of Environmental Health Sciences website and other auxiliary databases (https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html; https:// www.ncbi.nlm.nih.gov/snp/; https://www.ensembl.org/ index.html). The following criteria were used: minor allele frequency in Europeans >0.01, change in the amino acid chain, potential splicing site and/or miRNA binding site ( Figure 1 ). The rs35033501 polymorphism is one of the most commonly studied TERT SNPs. It represents a change of one proline codon (CCG) into another (CCA), without altering the amino acid sequence in the hTERT protein. This silent, synonymous mutation may potentially cause changes of splicing patterns or efficiency by disrupting splice sites. Similarly to rs35033501, the rs33954691 SNP also alters a splice site, potentially leading to changes in the splicing pattern. Another polymorphic variation investigated, rs2853690, is a common SNP in the 3ʹ untranslated region of the TERT gene. This cytosine-to-thymine substitution occurs in a locus responsible for miRNA binding, and may possibly affect miRNA-dependent mRNA stability and translation efficiency. The fourth SNP, rs2736100, was found to be a susceptibility factor for a variety of cancers and myeloproliferative neoplasms. The rs2736100 polymorphism is located in intron 2 of the TERT gene. Although its exact mechanism of action is unknown, several TERT (telomerase catalytic subunit) gene chromosome location: 5p15.33 Table S1 .
DNA isolation
DNA was isolated from 10 6 cultured cells of cancer and leukemia cell lines or from 5 mL of whole blood from CLL patients taken on EDTA using the Qiagen DNA Isolation Kit (Qiagen, Hilden, Germany) and following the recommendations of the manufacturer.
SNP genotyping of the TERT gene
The TERT polymorphic variants (rs2736100, rs2853690, rs33954691, rs35033501) in patients and controls were detected with the use of LightSNiP typing assays (TIB MOLBIOL, Berlin, Germany), employing real-time polymerase chain reaction (PCR) amplifications with melting curve analysis. The reactions were performed on a LightCycler 480 II Real-Time PCR system (Roche Diagnostics International, Rotkreuz, Switzerland), following the recommendations of the manufacturer.
VNTR MNS16A genotyping of the TERT gene
Presence of the MNS16A TERT gene polymorphism was assessed in all CLL patients and in healthy individuals. PCR was carried out in a 2720 Thermal Cycler instrument (Applied Biosystems, Foster City, CA, USA) using forward and reverse 
Notes: a OR=3.488, 95% CI 2.702-4.501, p=0.039. Abbreviations: SNP, single-nucleotide polymorphism; CLL, chronic lymphocytic leukemia.
primer sequences (5ʹ-AGGATTCTGATCTCTGAAGGGTG -3ʹ and 5ʹ-TAMRA-TCTGCCTGAGGAAGGACGTATG-3ʹ) prepared by Genomed (Warsaw, Poland), based on Wang etal. 24 The amplification procedure consisted of an initial denaturing step for 5 minutes at 95°C, followed by 35 cycles of: 30 seconds at 95°C, 45 seconds at 60°C and 1 minute at 72°C, as well as a final extension step for 10 minutes at 72°C. PCR products were diluted with formamide and GeneScan-500 ROX size standard (Applied Biosystems). Samples were denatured at 95°C for 5 minutes and quickly transferred to ice before analysis on the 3500 Genetic Analyzer (Applied Biosystems) with an eight-capillary system filled with the POP7 polymer. Alleles were identified with GeneMapper version 4.2 software (Applied Biosystems).
Telomere length analysis in CLL patients and human cancer cell lines Comparison of the SNP genotypes and allele frequencies (rs2736100, rs2853690 and rs33954691) between our CLL patients and healthy subjects did not show significant differences, suggesting no association with disease predisposition. However, it was observed that CLL patients were more often characterized by the presence of the rs35033501 A allele than healthy individuals (9/68 vs 4/99, OR=3.488, 95% CI 2.702-4.501, p=0.039), implying that the rs35033501 SNP may affect disease susceptibility ( Table 1) .
Distribution of various MNS16A VNTR genotypes and alleles: association with CLL stage at diagnosis
Six different alleles and 11 genotypes of MNS16A were identified and classified as either long (L) or short (S) according to the length of PCR fragments. 24 Carpentier et al. 41 The CLL patients and healthy subjects did not show significant differences in the MNS16A genotypes and allele frequencies. Genotype and allele distributions among CLL cases and healthy controls are presented in Table 2 . Some differences were noticed when stage of the disease at diagnosis was considered. According to the Rai and Binet criteria, 34 (Figure 2 ). Moreover, in CLL patients who had a low disease stage at diagnosis (0-I and A), the MNS16A VNTR-243 (short allele) occurred more frequently than in patients with advanced stage (II-IV, B-C), according to the Rai (28/45 vs 7/23, p=0.020) and Binet systems (30/50 vs 5/18, p=0.028) (Figure 3) . Thus, presence of the MNS16A VNTR-243 allele was more common in older patients with less advanced disease.
Relationships between VNTR MNS16A alleles and TERT SNP variants
The distribution of all genetic variants was compared between rs2736100, rs2853690, rs33954691 and rs35033501 polymorphisms and MNS16A tandem repeats. The TERT SNPs and MNS16A VNTR were not found to be in linkage disequilibrium (analyzed with Haploview 4.2 software: http://vassar stats.net/tab2x2.html) (Figure 4) . None of the studied SNP alleles was correlated with S or L VNTR alleles. We further examined whether there were any relationships between the most common MNS16A alleles (either 243 or 302 allele) and each SNP. However, no association between the presence of different genetic variants was observed.
Telomere length in CLL patients and in vitro cultured cell lines
Telomere length was analyzed in whole blood samples of 67 CLL patients at diagnosis (before treatment) and in eight cancer and leukemic cell lines cultured in vitro. The median of telomere length in patients was 5.71 kb. The median of telomere length in cell lines was even shorter and equaled 1.09 kb (Table S1) . Both in CLL patients and in in vitro cultured cell lines, telomere length was shorter than the median telomere length of 7.54 kb and 7.26 kb reported for healthy donors by Jebaraj et al 36 and Dos Santos et al, 37 respectively. No difference was observed between telomere length of female and malepatients. Similarly, patients below and over 60 years of age did notshow significant differences in telomere length. The latter observation is in line with the previous studies reporting a lack of correlation between telomere length and age of CLL patients. 9, 10, 42 Relationship between telomere length and VNTR and SNP genetic variants in CLL patients
It appeared that telomeres were longer in CLL patients (N=44) with less advanced stage of disease (0-I) compared to CLL patients (N=23) with more advanced disease (II-IV stage), according to the Rai criteria (7.95 vs 5.99 kb, p=0.030). Moreover, among CLL patients carrying the TERT rs2736100 C allele, telomeres were longer in patients (N=40) in a less advanced stage of disease (Binet A) in comparison to those (N=13) at Binet stage B or C (7.50 vs 4.55 kb, p=0.048) ( Figure 5A ). A similar relationship was observed when the Rai criteria were considered. In patients in a less advanced stage (0-I) possessing the TERT rs2736100 C allele (N=36), significantly longer telomeres were detected than in those carrying the C allele but diagnosed with stages II-IV (N=17) (7.86 vs 4.48 kb, p=0.010) ( Figure 5B ).
It was also observed that among CLL patients over 60 years of age, those carrying the VNTR-234 allele (N=27) had longer telomeres than patients lacking this allele (N=17) (with an average telomere length of 9.01 vs 6.03 kb, p=0.046) (Figure 6 ). For the other SNPs studied, no significant associations with telomere length were observed.
Discussion
Genetic variability within many genes can modulate telomere length and thus such genetic variants may constitute risk factors for the development of cancer and non-neoplastic diseases. 43, 44 Several studies suggest that genetically determined longer telomere length in peripheral leukocytes, also related with the TERT gene variants, could be associated with an increased risk of CLL. 16 Also, a positive relationship between telomere length and multiple non-Hodgkin's lymphoma (NHL) subtypes, particularly for CLL/SLL (small lymphocytic lymphoma), was reported. 15 The present retrospective study was conducted on a group of newly diagnosed untreated CLL patients. Assessment of telomere length, genetic factors related to TERT gene polymorphism, and identification of their relationships with susceptibility and clinical course of the disease were the key goals of this work. Therefore, four SNPs (rs2736100, rs2853690, rs33954691 and rs35033501) and the VNTR MNS16A gene polymorphism, all located within the TERT gene, were analyzed.
Results of a previous work by Ojha et al suggested some associations between CLL risk and the rs2736100 C allele that were not observed in the present study. 16 Comparison of rs2736100, rs2853690, rs33954691, rs35033501 and VNTR MNS16A genotypes and allele frequencies between our CLL patients and healthy individuals did not indicate significant differences, except for the rs35033501 minor A variant. This variant was more frequently detected in CLL patients than in healthy controls, and was associated with a greater than threefold increase in risk for CLL development. The rs35033501 polymorphism is a synonymous substitution that does not affect the amino acid sequence. However, such silent variants may potentially cause changes of splicing patterns.
Many recent studies have focused on the role of various factors affecting splicing in patients with CLL. The study by Palma et al aimed to characterize hTERT splice variants in CLL cells, as well as to examine the expression of hTERT splice variants and telomere length in relation to disease activity and clinical stage. The authors described two splicing sites that generate shorter transcripts and one full-length transcript that is translated into a functional protein. They observed that all transcripts were more frequently expressed in progressive than non-progressive patients and showed that average fulllength transcript expression was 5.5-fold higher in immunoglobulin heavy chain variable region (IGHV)-unmutated CLL patients than in IGHV-mutated patients. 44 A mutation within the splicing factor SF3B1 (splicing factor 3b subunit 1) gene in CLL was identified.
45 SF3B1
encodes a protein involved in binding of the spliceosomal U2 snRNP to the branch point of the 3′ splicing site. Truncation of the protein by the introduction of premature stop codons is the most common outcome of splicing aberrations induced by SF3B1 mutations, affecting 90% of cases. In CLL, SF3B1 mutations are more frequent in later stages of the disease; they are associated with markers of poor clinical outcome and predict poor prognosis. 45 In addition, genetic variability within other genes was reported to affect splicing in CLL patients. Puente et al identified novel recurrent mutations in non-coding regions, including the 39th region of notch receptor 1 (NOTCH1), which cause aberrant splicing events, increase NOTCH1 activity and result in a more aggressive disease. 46 The aforementioned results show that various factors could affect splicing in patients with CLL, including genetic variability within non-coding regions also observed for the TERT rs35033501 SNP in the present study. Furthermore, some of these factors could be related to clinical parameters of the disease.
The polymorphic number of MNS16A tandem repeats was reported to be associated with the risk of several malignancies, including lung 24, 47 or colorectal and prostate cancer, 38,39 malignant gliomas, 40, 41 as well as Alzheimer's disease. 48 So far, the MNS16A VNTR polymorphism of the hTERT catalytic subunit has been described in two lymphoproliferative disorders: first in our study on NHL, 27 and later in diffuse large B-cell lymphoma (DLBCL). 49 Our previous work identified some relationships between the VNTR-243 variant with more aggressive disease and with less favorable response to therapy. 27 The study on DLBCL revealed that Egyptian carriers of the S allele or the SS genotype of MNS16A were at higher risk of disease development. 49 Wang et al investigated promoter activity of MNS16A VNTRs in lung cancer cells and showed that the shorter VNTR (S) variant correlated with lower promoter activity, while the longer VNTR (L) was associated with increased risk of lung cancer. 24 Hofer et al investigated promoter activity of all six known MNS16A VNTRs in different cell lines and showed the distribution of relative promoter activities of different MNS16A VNTRs determined by luciferase reporter assays. In all investigated cell lines, promoter activity of shorter constructs (also VNTRs-234) was higher than promoter activity of longer constructs, reflecting an indirect correlation between VNTR length and promoter activity. 25 In addition, Zhang et al observed that carriers of the SL genotype had lower TERT expression compared to LL carriers when analyzing nasopharyngeal carcinoma tissue by immunohistochemical staining. 26 The current results suggest a lack of association between the MNS16A TERT genetic polymorphism and predisposition to CLL. However, there were some interesting observations in regard to the MNS16A VNTR-243 short allele, which was more frequently detected in patients with less advanced disease (Rai 0-I and Binet A) than in patients with Rai II-IVand Binet B or C. These results are consistent with previous data showing a correlation between the presence of short MNS16A genotypes or alleles and advanced age at diagnosis of patients with prostate cancer or nasopharyngeal carcinoma and breast cancer. 38, 50 They imply that the presence of the MNS16A
VNTR-243 short allele may affect the course of the disease. Indeed, in our previous study the presence of the MNS16A VNTR-243 short allele was found to play a role in progression and response to therapy of NHL patients. 27 In various cancer scenarios, a dual role of telomere length has been observed. In general, in most patients who develop cancer the presence of long telomeres in tumor-initiating cells was detected. However, it is also well documented that critically short telomeres may lead to chromosomal instability, which can cause tumorigenesis. As for CLL, telomere dysfunction was observed in advanced stages of the disease, when the presence of critically short telomeres correlated with the occurrence of many genome rearrangements. 11, 12, [51] [52] [53] Moreover, several studies showed that early-stage CLL patients exhibited extensive telomere erosion and fusion, indicating that telomere shortening and dysfunction can precede clinical progression. 9, 54 Also, no significant difference was observed between telomere length measured in tumor Figure 6 Relationship between telomere length and the presence of VNTR alleles in older patients. Among CLL patients over 60 years of age, those carrying the VNTR-234 allele had longer telomeres than patients lacking this allele (with an average telomere length of 9.01 vs 6.03 kb, p=0.046).
Abbreviations: VNTR, variable number of tandem repeats; CLL, chronic lymphocytic leukemia. Figure 5 Telomere length in patients with varying severity of the disease. In patients carrying the TERT rs2736100 C allele, longer telomeres were associated with less advanced disease according to the Rai staging system (A) and the Binet criteria (B).
cells and in healthy cells of these CLL patients (Binet stage A and Rai stage 0). The study by Hoxha et al indicated the association between telomere status and genomic instability in CLL and found a significant correlation between telomere shortening and DNA hypomethylation in an early phase of disease. 9 These results suggested that impairment of the telomere/telomerase system may represent an early event in CLL pathogenesis. 9 We observed that CLL patients at a less advanced stage (Rai 0-I) at diagnosis had significantly longer telomeres than those with Rai stage II-IV, although their median telomere length equaled 5.71 kb and was shorter than median telomere length of 7.54 kb and 7.26 kb reported for healthy donors by Jebaraj et al 36 and Dos Santos et al, 37 respectively. Moreover, significantly longer telomeres were observed among patients with less advanced disease (Rai 0-I or Binet A) possessing the TERT rs2736100 C allele, compared to patients with the TERT rs2736100 C allele, but exhibiting more advanced CLL stage (Rai III-IV or Binet B-C) (7.50 vs 4.55 kb and 7.86 vs 4.48 kb, for the Rai and Binet criteria, respectively). The observations above are in line with data from the Ojha et al study, which described the rs2736100 C allele as being associated with long leukocyte telomere length in a group of CLL patients. 16 A common genetic variant in the TERT gene, rs2736100 C/A, is associated with both telomere length and risk in various diseases. This effect, however, was not directly visible in our CLL patients. A large meta-analysis performed by Snetselaar et al showed various effects of the TERT rs2736100 polymorphism in different disease association studies. 55 Cancer cases were more often characterized by the presence of the TERT rs2736100 C allele, while for non-malignant diseases positive associations of the TERT rs2736100 A allele with disease risk were observed. 55 Thus, the results of Snetselaar et al reflect a fundamentally different role of telomere biology in malignancies as opposed to non-malignant diseases, and illustrate the duality of telomere biology in different disease predisposition. 55 In addition, the strength of the effect of rs2736100 polymorphism may vary between populations, as shown, for example, for Swedish and Chinese males with myeloproliferative neoplasms by Dahlström et al. 56 In conclusion, the current results focusing on SNPs and the MNS16A polymorphism of the TERT gene and telomere length in CLL patients may add new valuable information to the knowledge regarding potential significance of telomere length/telomerase activity and expression in hematological malignancies. We showed that older CLL patients, who carried the MNS16A VNTR-243 short allele, were characterized by lower disease stage at diagnosis. That may be a result of a higher telomerase activity than that observed in patients with the long/long genotype and the long allele. Carriers of the long allele were previously shown to exhibit stronger TERT promoter activity and to carry the highest number of GATA-1 transcription factor binding sites, which leads to increased expression of antisense TERT mRNA and silencing of the sense telomerase transcript.
As SNPs may affect mRNA expression via splicing sites and/or miRNA binding site modifications, their detection within the TERT gene offers new prognostic opportunities. The current results also show an association between the rs35033501 A allele and disease susceptibility. Moreover, especially among patients possessing the TERT rs2736100 C allele, an association between telomere length and severity of the disease at diagnosis was observed.
Our results may help researchers to understand CLL development and identify new genetic biomarkers involved in this disease. The present study was particularly novel because it was the first to address the issue of TERT genetic variants (a VNTR and SNPs) in relation to telomere length in a hematological disorder. However, we are aware that our results should be further supported by functional tests of TERT expression in large groups of patients. Nevertheless, understanding the TERT polymorphism and expression in the context of CLL progression is an important step toward finding new ways to improve clinical care.
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